d(GC) - Association of Biotechnology and Pharmacy
d(GC) - Association of Biotechnology and Pharmacy
d(GC) - Association of Biotechnology and Pharmacy
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Current Trends in <strong>Biotechnology</strong> <strong>and</strong> <strong>Pharmacy</strong><br />
Vol. 6 (2) 229-240 April 2012, ISSN 0973-8916 (Print), 2230-7303 (Online)<br />
Acknowledgement<br />
The authors thank Dr Parvin Shariati for<br />
critical reading <strong>of</strong> the manuscript.<br />
Funding: We gratefully acknowledge the<br />
financial grant received from the National Institute<br />
<strong>of</strong> Genetic Engineering <strong>and</strong> <strong>Biotechnology</strong> (No.<br />
298).<br />
References<br />
1. Baker, D.P., Lin, E.Y., Lin, K., Pellegrini, M.,<br />
Petter, R.C., Chen, L.L., Arduini,<br />
R.M.,Brickelmaier, M., Wen, D., Hess,<br />
D.M., Chen, L., Grant, D., Whitty, A., Gill,<br />
A., Lindner, D.J. <strong>and</strong> Pepinsky, R.B. (2006).<br />
N-Terminally PEGylated Human Interferonβ-1a<br />
with Improved Pharmacokinetic<br />
Properties <strong>and</strong> in Vivo Efficacy in a<br />
Melanoma Angiogenesis Model. Bioconj<br />
Chem, 17(1):179-188.<br />
2. Chevaliez, S. <strong>and</strong> Pawlotsky, J.M. (2007).<br />
Interferon-based therapy <strong>of</strong> hepatitis C. Adv<br />
Drug Del Rev, 59(12):1222-1241.<br />
3. Souvignet, C., Lejeune, O. <strong>and</strong> Trepo, C.<br />
(2007). Interferon-based treatment <strong>of</strong><br />
chronic hepatitis C. Biochimie, 89(6-7):894-<br />
898.<br />
4. Tayal, V. <strong>and</strong> Kalra, B.S. (2008). Cytokines<br />
<strong>and</strong> anti-cytokines as therapeutics—an<br />
update. Eur J Pharmaco, 579(1-3):1-12.<br />
5. Esmata, G. <strong>and</strong> Abdel Fattah, S. (2009).<br />
Evaluation <strong>of</strong> a novel pegylated interferon<br />
alpha-2a in Egyptian patients with chronic<br />
hepatitis C– genotype 4. Digest Liver Dis,<br />
Suppl. 3:17-19.<br />
6. Van Beers, M.M.C., Sauerborn, M., Gilli, F.,<br />
Hermeling, S., Brinks, V., Schellekens, H.<br />
<strong>and</strong> Jiskoo, W. (2010). Hybrid transgenic<br />
immune tolerant mouse model for<br />
assessing the breaking <strong>of</strong> B cell tolerance<br />
Ahmad Abolhasani et al<br />
238<br />
by human interferon beta. J Immunol<br />
Methods, 352(1-2):32-37.<br />
7. Harris, J.M. <strong>and</strong> Chess, R.B. (2003). Effect<br />
<strong>of</strong> pegylation on pharmaceuticals. Nat Rev<br />
Drug Discov, 2(3):214-221.<br />
8. Veronese, F.M. <strong>and</strong> Pasut, G. (2005).<br />
PEGylation, successful approach to drug<br />
delivery. Drug Discov Today, 10(21):1451-<br />
1458.<br />
9. Roberts, M.J., Bentley, M.D. <strong>and</strong> Harris,<br />
J.M. (2002). Chemistry for peptide <strong>and</strong><br />
protein PEGylation. Adv Drug Deli Rev,<br />
54(4):459-476.<br />
10. Caliceti, P. <strong>and</strong> Veronese, F.M. (2003).<br />
Pharmacokinetic <strong>and</strong> biodistribution<br />
properties <strong>of</strong> poly(ethylene glycol)-protein<br />
conjugates. Adv Drug Del Rev, 55:1261-<br />
1277.<br />
11. Na, D.H., Youn, Y.S., Lee, I.B., Park, E.J.,<br />
Park, C.J. <strong>and</strong> Lee, K.C. (2006). Effect <strong>of</strong><br />
molecular size <strong>of</strong> PEGylated recombinant<br />
human epidermal growth factor on the<br />
biological activity <strong>and</strong> stability in rat wound<br />
tissue. Pharm Dev Technol, 11:513-519.<br />
12. Monkarsh, S.P., Ma, Y., Aglione, A., Bailon,<br />
P., Ciolek, D., Debarbieri, B., Graves, M.<br />
C., Hollfelder, K., Michel, H., Palleroni, A.,<br />
Porter, J.E., Russoman, E., Roy, S. <strong>and</strong><br />
Pan, Y.C. (1997). Positional isomers <strong>of</strong><br />
monopegylated interferon alpha-2a:<br />
isolation, characterization, <strong>and</strong> biological<br />
activity. Anal Biochem, 247:434-440.<br />
13. Bailon, P., Palleroni, A., Schaffer, C.A.,<br />
Spence, C.L., Fung, W.J., Porter, J.E.,<br />
Ehrlich, G.K., Pan, W., Xu, Z.X., Modi,<br />
M.W., Farid, A., Berthold, W. <strong>and</strong> Graves,<br />
M. (2001). Rational design <strong>of</strong> a potent, longlasting<br />
form <strong>of</strong> interferon: a 40 kDa<br />
branched polyethylene glycol conjugated<br />
interferon alpha-2a for the treatment <strong>of</strong><br />
hepatitis C. Bioconj Chem, 12:195-202.